The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The Tuberculosis Drug Discovery and Development Pipeline and Emerging Drug Targets
Open accessAbstract
The recent accelerated approval for use in extensively drug-resistant and multidrug-resistant-tuberculosis (MDR-TB) of two first-in-class TB drugs, bedaquiline and delamanid, has reinvigorated the TB drug discovery and development field. However, although several promising clinical development programs are ongoing to evaluate new TB drugs and regimens, the number of novel series represented is few. The global early-development pipeline is also woefully thin. To have a chance of achieving the goal of better, shorter, safer TB drug regimens with utility against drug-sensitive and drug-resistant disease, a robust and diverse global TB drug discovery pipeline is key, including innovative approaches that make use of recently acquired knowledge on the biology of TB. Fortunately, drug discovery for TB has resurged in recent years, generating compounds with varying potential for progression into developable leads. In parallel, advances have been made in understanding TB pathogenesis. It is now possible to apply the lessons learned from recent TB hit generation efforts and newly validated TB drug targets to generate the next wave of TB drug leads. Use of currently underexploited sources of chemical matter and lead-optimization strategies may also improve the efficiency of future TB drug discovery. Novel TB drug regimens with shorter treatment durations must target all subpopulations of Mycobacterium tuberculosis existing in an infection, including those responsible for the protracted TB treatment duration. This review summarizes the current TB drug development pipeline and proposes strategies for generating improved hits and leads in the discovery phase that could help achieve this goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
Natural products as sources of new drugs over the 30 years from 1981 to 2010
Newman, D. J., & Cragg, G. M. (2012) · Journal of Natural Products · doi:10.1021/np200906s · Cited by 4,687
Genes required for mycobacterial growth defined by high density mutagenesis
Sassetti, C. M., Boyd, D. H., & Rubin, E. J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03425.x · Cited by 2,544
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 2×
“ATP synthesis and PMF generation are among the best-validated Mtb drug targets owing to the clinical successes of the ATP synthase inhibitor TMC207 (bedaquiline, Sirturo) (Andries et al. 2005; Diacon et al. 2009) and the cornerstone TB drug pyrazinamide, which disrupts the PMF (Zhang et al.”
BackgroundIron Metabolism in Pathogenic Bacteria
Ratledge, C., & Dover, L. G. (2000) · Annual Review of Microbiology · doi:10.1146/annurev.micro.54.1.881 · Cited by 1,539
Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages
Schnappinger, D., Ehrt, S., Voskuil, M. I., Liu, Y., Mangan, J. A., Monahan, I. M., Dolganov, G., Efron, B., Butcher, P. D., Nathan, C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030846 · Cited by 1,420
Mycobacterial persistence requires the utilization of host cholesterol
Pandey, A. K., & Sassetti, C. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711159105 · Cited by 1,064
Griffin, J. E., Gawronski, J. D., DeJesus, M. A., Ioerger, T. R., Akerley, B. J., & Sassetti, C. M. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002251 · Cited by 1,048
Essential Role for Cholesterol in Entry of Mycobacteria into Macrophages
Gatfield, J., & Pieters, J. (2000) · Science · doi:10.1126/science.288.5471.1647 · Cited by 615
The Enduring Hypoxic Response of Mycobacterium tuberculosis
Rustad, T. R., Harrell, M. I., Liao, R., & Sherman, D. R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001502 · Cited by 491
Discovery of a Siderophore Export System Essential for Virulence of Mycobacterium tuberculosis
Wells, R. M., Jones, C. M., Xi, Z., Speer, A., Danilchanka, O., Doornbos, K. S., Sun, P., Wu, F., Tian, C., & Niederweis, M. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003120 · Cited by 267
Iron metabolism and the innate immune response to infection
Johnson, E. E., & Wessling-Resnick, M. (2012) · Microbes and Infection · doi:10.1016/j.micinf.2011.10.001 · Cited by 253
Fumarate Reductase Activity Maintains an Energized Membrane in Anaerobic Mycobacterium tuberculosis
Watanabe, S., Zimmermann, M., Goodwin, M. B., Sauer, U., Barry, C. E., & Boshoff, H. I. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002287 · Cited by 246
Holmes, M. A., Paulsene, W., Jide, X., Ratledge, C., & Strong, R. K. (2005) · Structure · doi:10.1016/j.str.2004.10.009 · Cited by 246
Host-Pathogen Interactions: The Role of Iron1,
Doherty, C. P. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.5.1341 · Cited by 186
Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB
Abrahams, K. A., Cox, J. A. G., Spivey, V. L., Loman, N. J., Pallen, M. J., Constantinidou, C., Fernández, R., Alemparte, C., Remuiñán, M. J., Barros, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052951 · Cited by 177
Characterization of the cydAB -Encoded Cytochrome bd Oxidase from Mycobacterium smegmatis
Kana, B. D., Weinstein, E. A., Avarbock, D., Dawes, S. S., Rubin, H., & Mizrahi, V. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.24.7076-7086.2001 · Cited by 153
Dhiman, R. K., Mahapatra, S., Slayden, R. A., Boyne, M. E., Lenaerts, A., Hinshaw, J. C., Angala, S. K., Chatterjee, D., Biswas, K., Narayanasamy, P., et al. (2009) · Molecular Microbiology · doi:10.1111/j.1365-2958.2009.06625.x · Cited by 146
Matsoso, L. G., Kana, B. D., Crellin, P. K., Lea-Smith, D. J., Pelosi, A., Powell, D., Dawes, S. S., Rubin, H., Coppel, R. L., & Mizrahi, V. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.18.6300-6308.2005 · Cited by 134
Self-poisoning of Mycobacterium tuberculosis by interrupting siderophore recycling
Jones, C. M., Wells, R. M., Madduri, A. V. R., Renfrow, M. B., Ratledge, C., Moody, D. B., & Niederweis, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311402111 · Cited by 125
Cited by
Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets
Alsayed, S. S. R., & Gunosewoyo, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065202 · Cited by 332
New agents for the treatment of drug-resistant Mycobacterium tuberculosis
Hoagland, D. T., Liu, J., Lee, R. B., & Lee, R. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.026 · Cited by 328
Metadata
- Authors
- Mdluli, K., Kaneko, T., & Upton, A.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2015-01-29
- Volume
- 5
- Issue
- 6
- Pages
- a021154-a021154
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2167156367
- Cited by
- 180
- References
- 22
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.